Please ensure Javascript is enabled for purposes of website accessibility

Why Retrophin Inc was Down Today

By Brian Feroldi – Feb 10, 2016 at 1:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of an incoming competitor pushed shares lower in early trading.

What: Shares of Retrophin (TVTX 2.90%), a small-cap biopharmaceutical company focused primarily on treating rare diseases, were down by as much as 10% as of 11:00 a.m. EST Wednesday after news broke that there is could be new competition on the horizon for one of its key drugs. The shares have since bounced back.

So what: Compounding pharmaceutical company Imprimis Pharmaceuticals announced on Wednesday it will be offering a delayed release formulation that will compete directly with Retrophin's Thiola, a drug used to treat cystinuria. Imprimis's CEO said the the aim of the introduction is to give patients a lower cost therapeutic alternative. The formulations is expected to be available in April.

Imprimis' is able to bring this product to market quickly because it is a compounding pharmacy. Unlike drug manufactures that have to go through the FDA approval process when they want to introduce new drugs, compounding pharmacies bypass that step by customizing pre-approved drug compounds for individual patient use.

Imprimis Pharmaceuticals CEO Mark Baum stated "All we're doing is offering competition to those drugs that the FDA under oath has said publicly will not have generic competition."

Now what: Cystinuria is a chronic, rare disease that affects roughly 10,000 Americans and is chronic disease that causes patient's bodies to turn amino acid into stones primarily in the kidney, ureter, and bladder. Retrophin's Thiola helps to prevent the formation of the stones and around half the patients with the disease in the U.S. are currently candidates using the drug.

Thiola has an interesting history as it wasn't a home grown compound created by Retrophin. Instead it was acquired in 2014 while none other than Martin Shkreli was still in charge. After getting a hold of the drug Shkreli immediately raised the price of Thiola 2,000%, causing some patients with cystinuria to suddenly be facing therapy costs of up to $100,000 per year.

Shkreli's has since been throw out of the top seat at Retrophin and the company went so far as to sue him for $65 million, but it has not lowered the price of the Thiola at all.

It's unclear what kind of financial impact this move could have on Retrophin's financials if patients and providers do opt to use the compounded version of Thiola in 2016.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Travere Therapeutics, Inc. Stock Quote
Travere Therapeutics, Inc.
$25.36 (2.90%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.